Emergence of mucormycosis following second wave of COVID-19 pandemic and possible risk factors in a hilly state of North India
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20220253Keywords:
Mucormycosis, Emergence, COVID-19 second wave, Risk factorsAbstract
Background: Mucormycosis is a rare, highly aggressive fungal infection affecting the rhino-orbital, respiratory, gastrointestinal or cutaneous systems and is caused by a group of moulds called mucoromycetes belonging to order Mucorales and has been associated with corona pandemic. The aim of the study was to assess the emerging trends of mucormycosis following second wave of Corona pandemic and possible risk factors in a hilly state of North India.
Methods: It was a retrospective data analysis study where the information’s were gathered from various sources in state of Himachal Pradesh. After detection of 1st case, data was collected from May 2021 to July 2021. Since objective and authentic data was released by different agencies daily, so the state profile of mucormycosis cases was taken as per information available from newspapers, various state websites and analysed for various parameters.
Results: The current study conducted in state of Himachal Pradesh showed that Hamirpur was the worst hit district with affected population 0.002%, with case fatality rate 57%. While male mortality was more (60%) as compared to female mortality (40%).
Conclusions: This study showed that underlying risk factors for mucormycosis were COVID-19 infection, un-controlled diabetes, steroid and oxygen use.
References
Adam RD, Hunter G, Tomasso J, Comerci G. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19(1):67-76.
Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009;15(5):2-9.
Suthananthan AE, Koek SA, Sieunarine K. Cutaneous mucormycosis in an immunocompromised patient: a case report. J Surg Case Rep. 2017;2017(3):56.
B inder U, Maurer E, Flörl C. Mucormycosis--from the pathogens to the disease. Clin Microbiol Infect. 2014;20(6):60-6.
Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(1):55-60.
Prakash H, Ghosh AK, Rudramurthy SM, Singh P, Xess I, Savio J, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol. 2019;57(4):395-402.
Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 20191;5(1):26.
Bitar D, Lortholary O, Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20(7):1149-55.
Neblett FR, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214-25.
Patiño JF, Castro D, Valencia A, Morales P. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg. 1991;15(2):240-7.
Chakarbarti A, Sood P, Denning D. Estimating fungal infection burden in India using computational models: Mucormycosis burden as a case study. Germany: 23rd ECCMID conference Berlin; 2014.
Chakrabarti A, Singh R. The emerging epidemiology of mould infections in developing countries. Curr Opin Infect Dis. 2011;24(6):521-6.
Arendrup MC, Jensen RH, Meletiadis J. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrob Agents Chemother. 2015;59(12):7735-42.
Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.
